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INTRODUCTION
Androgen receptor (AR) plays a critical role in the progression of prostate cancer. Prostate cancer is initially dependent on the ligand of AR, androgen, and androgen deprivation therapy is effective. However, over time, most patients develop androgenindependent disease, which no longer responds to hormonal therapies. Importantly, even at this advanced stage of androgen-independent disease, most tumors are still dependent on continued expression and activation of AR. Therefore, targeting AR is a promising approach to treat advanced prostate cancer. This project is directed towards testing the feasibility of targeting AR for lysosomal degradation. While most cellular proteins turn over by ubiquitin-proteasome-dependent mechanism, steroid hormone receptors including AR were recently shown to be substrates of lysosomal degradation [1] . Although AR is also known to be degraded by ubiquitin-proteasome-dependent mechanism [2] , the cellular pool of AR could be depleted by enhancing its lysosomal degradation. An important untested hypothesis, which will be tested in this project, is whether enhanced lysosomal degradation of AR can be used to target AR. To increase the lysosomal degradation, we will use either exogenous TFEB expression or a pharmacological activator of the TFEB -lysosome degradation pathway, torin 1, and test their effects on AR degradation.
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ACCOMPLISHMENTS
In mid-2009, a transcription factor, TFEB, was shown to function as a master regulator of lysosomal biogenesis [3] . The activity of TFEB is controlled by cytoplasmic sequestration, which is regulated by mTOR-mediated phosphorylation [4] [5] [6] . A potent mTOR active-site inhibitor, torin 1, was shown to efficiently induce the nuclear translocation of TFEB [4] [5] [6] . In contrast, rapamycin, an mTOR allosteric inhibitor that only incompletely inhibits mTOR activity, did not induce TFEB nuclear translocation at any of the concentrations that are routinely used (10 nM -10 μM) [4, 5] . Therefore, by overexpressing TFEB or by inducing TFEB nuclear translocation using torin 1, lysosomal biogenesis can be induced, which could be employed to degrade AR in prostate cancer.
In order to test the effect of TFEB on AR degradation, we generated the expression vectors for TFEB. We obtained a cDNA for human full-length TFEB, added a FLAG-tag at the N-terminus of TFEB using PCR, verified the DNA sequence of PCR-amplified cDNA, and cloned the tagged TFEB cDNA to pcDNA3 and pCDF1 expression vectors. We packaged the pCDF1-FLAG-TFEB lentivirus by co-transfection in 293T cells with pFIV-34N and pVSV-G packaging plasmids and generated the lentivirus expressing FLAG-TFEB. Robust expression of TFEB was verified by anti-FLAG immunoblotting of cell lysates prepared from cells infected with pCDF1-FLAG-TFEB lentivirus as well as cells transfected with pcDNA3-FLAG-TFEB expression vector. Additionally, anti-TFEB 5 immunoblotting demonstrated 5~10-fold increased levels of TFEB expression in cells infected with pCDF1-FLAG-TFEB lentivirus and in cells transfected with pcDNA3-FLAG-TFEB expression vector, compared with control cells expressing endogenous levels of TFEB. As mentioned above, the subcellular location of endogenous TFEB is regulated by mTOR-mediated phosphorylation. We therefore mutated the mTOR phosphorylation site in TFEB (S211A) to test whether TFEB S211A mutant displays more nuclear localization and hence would be more effective in inducing lysosomal biogenesis. Under the conditions of lentiviral expression or transient transfection, we did not observe increased nuclear localization of TFEB S211A compared with wild-type TFEB (both were mainly nuclear), suggesting that when exogenously expressed, a sufficient amount of wild-type TFEB localizes in the nucleus to induce the gene expression program for lysosomal biogenesis [3] .
Using GFP-tagged AR expression vector, we were able to show that TFEB induces the degradation of GFP-AR ( Figure 1A ). The endogenous TFEB activity is regulated by mTOR-dependent phosphorylation [4] [5] [6] . Phosphorylation by mTOR results in sequestration of TFEB in the cytoplasm and inhibition of lysosomal biogenesis. The activity of mTOR is negatively regulated by the TSC1/TSC2 tumor suppressor complex. A hypoxia-inducible protein, REDD1, was shown to inhibit the mTOR activity through TSC1/TSC2 [7] . Consistent with this, co-expression of REDD1 resulted in reduced GFP-AR protein levels ( Figure 1A ).
We have also analyzed the effect of LAMP2 and HSPA8, two key components of chaperone-mediated autophagy (CMA) on the AR protein levels, to assess the role of CMA in the lysosomal degradation of AR. Co-expression of LAMP2, which serves as a receptor and lysosomal import cargo for CMA substrates, significantly reduced GFP-AR expression ( Figure 1A ). LAMP2 co-expression was also shown to reduce the protein levels of HIF-1α, a recently proposed CMA substrate [8] . Additionally, co-expression of HSPA8 also slightly reduced GFP-AR protein levels ( Figure 1A ) as was the case for HIF-1α [8] . These results suggest a possible involvement of chaperone-mediated 6 autophagy in the lysosomal degradation of AR. While the link between the TFEBlysosome pathway and chaperone-mediated autophagy is not yet established, chaperone-mediated autophagy might explain how AR is transported to the lysosome for degradation when the TFEB -lysosome pathway is activated.
As mentioned earlier, a kinase inhibitor of mTORC1, torin 1, potently inhibits the mTORC1 activity, leading to increased nuclear translocation of endogenous TFEB. We found that torin 1 reduced the protein levels of GFP-AR ( Figure 1B) . This is consistent with that inhibition of mTORC1 activity and activation of TFEB by torin 1 causes the degradation of AR.
GFP-AR was located in the nucleus and cytoplasmic dot-like structures. GFP-AR was also located in the nucleus and cytoplasmic dot-like structures upon TFEB coexpression or torin 1 treatment, suggesting that activation of the TFEB -lysosome pathway results in AR degradation without altering the subcellular location of AR.
These results support our central hypothesis that AR can be targeted for degradation by stimulating its lysosomal degradation via the TFEB -lysosome biogenesis pathway.
We then tested the effect of TFEB on endogenous AR in prostate cancer cell lines. LNCaP and 22Rv1 prostate cancer cell lines were infected with pCDF1-FLAG-TFEB lentivirus or pCDF1 vector virus. Two days after infection, cells were selected with 2 µg/ml puromycin for 2 days. The expression of AR was determined by immunoblotting using anti-AR antibody (D6F11, Cell Signaling Technology). As shown in Figure 2 , the expression of TFEB reduced the levels of endogenous AR protein in prostate cancer cells, suggesting that the stimulation of TFEB -lysosome biogenesis pathway can be used to target endogenous AR in prostate cancer. While TFEB reduced AR levels in prostate cancer cells, we did not observe significant proliferation inhibition or apoptosis induction upon TFEB expression.
We also tested the effect of torin 1 treatment on endogenous AR in prostate cancer cells. LNCaP and 22Rv1 cells were treated with 0, 125, 250, 500, or 1000 nM torin 1 for 24 hours and the AR protein levels were determined by anti-AR immunoblotting. As shown in Figure 3 , torin 1 treatment did not reduce the AR protein levels in prostate cancer cells although torin 1 effectively abolished the phosphorylation of S6 kinase, the phosphorylation substrate of mTORC1, indicating that torin 1 effectively suppressed mTORC1 kinase activity.
Additionally, we have used the same reagents developed by the course of this project to demonstrate the role of the TFEB -lysosome pathway in the turnover of EWS-Fli-1, a fusion oncoprotein of Ewing sarcoma (Note the research expenses for this experiment were paid by the institutional pilot grant, not by the present Department of Defense grant, but we acknowledged the support by this Department of Defense grant in our publication [9] ).
We demonstrated that EWS-Fli-1 can be efficiently targeted for degradation by TFEB ( Figure 4A ) and a lysosomal protease, cathepsin D, can proteolyze EWS-Fli-1 both in 293 cells ( Figure 4B ) and in A673 Ewing sarcoma cells ( Figure 4C ). We went on to demonstrate that torin 1 treatment results in degradation of endogenous EWS-Fli-1 in A673 and TC71 Ewing sarcoma cells ( Figure 4D ), suggesting a novel therapeutic approach to target EWS-Fli-1 for degradation by stimulating the TFEB -lysosome degradation pathway. The paper describing this finding was published in the Journal of Proteome Research [9] 
IMPACT
• Demonstration of the feasibility of targeting AR for degradation by stimulation of the TFEB -lysosome pathway in prostate cancer cells.
• Demonstration of the feasibility of targeting EWS-Fli-1 for degradation by the TFEB -lysosome pathway in Ewing sarcoma cells.
CHANGES/PROBLEMS
Nothing to report. 
• INTRODUCTION
Ewing sarcoma is the second most common malignancy of bone and soft tissues in children and young adults and is characterized by a chromosomal translocation that generates a fusion oncogene between EWS and an Ets family transcription factor, most commonly Fli 1.
1 -5 EWS Fli 1 fusion accounts for 85% of Ewing sarcoma cases. Ewing sarcoma is an aggressive tumor with relatively poor long term outcome. Overall survival is approximately 60%, and the five year survival of recurrent cases is less than 10%. Considering that current cytotoxic chemotherapies used for Ewing sarcoma are not improving the survival of metastatic or recurrent disease, a new approach for targeted therapy needs to be developed. 1 -5 The growth and survival of Ewing sarcoma cells critically depend on the EWS Fli 1 fusion oncoprotein.
1 --6 Therefore, targeting EWS Fli 1 is a promising approach to treat Ewing sarcoma. However, despite a number of attempts, an EWS Fli 1 targeted therapy has not materialized to date and EWS Fli 1 continues to be "the perfect target without a therapeutic agent"? EWS Fli 1 is a transcription factor that controls the expression of a number of genes important for cell proliferation and transformation. actome. The result from the interactome analyses was used to provide leads for subsequent molecular biological analyses. Using a tandem affinity purification approach, we identified known EWS Fli 1 interactors such as EWS 8 and RNA helicase A 9 Using a proximity dependent biotinylation technique, BioiD, 10 we identified cation independent mannose 6 phos phate receptor ( CIMPR) as a protein located in the vicinity of EWS Fli 1 within a cell. CIMPR is a cargo that mediates the sorting of lysosomal hydrolase precursors from the trans Golgi network to endosomes.
11 Additional molecular cell biological analyses revealed that the EWS Fli 1 protein turns over by a lysosome dependent mechanism. We show that torin 1, which is an active site inhibitor of mTORC1 that was shown to stimulate the TFEB lysosome pathway, can reduce EWS Fli 1 protein levels in Ewing sarcoma cells, suggesting a potential utility of mTORC1 active site inhibitors as therapy for Ewing sarcoma.
• EXPERIMENTAL PROCEDURES
Reage nts
Chloroquine and pepstatin A were purchased from MP Biomedicals. Doxorubicin was purchased from Sigma Aldrich. protocol, and the cells infected with lentiviruses were selected with 2 pg/mL puromycin for 48 h as described 12 '
13 Luciferase assays were done as described 13 
Protein Sample Preparation and Mass Spectrometry
Tandem Affinity Purification of FLAG-His-EW5-Fii-1-lnteracting Proteins. Forty 15 em plates of 293T cells were transfected with FLAG His EWS Fli 1 {type 1 fusion); 48 h after transfection, the cells were lysed in TN buffer (10 mM Tris pH 7.4/150 mM Na0/1% NP 40/1 mM AEBSF/10 pg/ mL aprotinin/10 pg/mL Leupeptin/1 pg/mL Pepstatin A/20 mM sodium fluoride). The lysate was incubated with Ni NTA agarose (Qiagen), FLAG His EWS Fli 1 and its interacting proteins were collected by centrifugation, washed three times with TN buffer, and eluted with 50 mM sodium phosphate buffer pH 8.0/150 mM NaCI/250 mM imidazole. The eluted sample was immunopredpitated with anti FLAG antibody (M2, Sigma Aldrich), the immunoprecipitate was eluted with FLAG peptide (Sigma Aldrich), and the eluted protein sample was processed with an Amicon Ultra 0.5 3k centrifugal filter device {Millipore) for concentration and buffer exchange to 50 mM Tris pH 8.5. Proteins were digested at 37 °C overnight with trypsin (Promega; 1:10, enzyme/substrate) in the presence of 10% acetonitrile (ACN). The pH of the digestion solution was adjusted to 7.5 with 1 mM ammonium bicarbonate, if necessary. The resulting tryptic peptides were analyzed by HPLC ESI tandem mass spectrometry (HPLC ESI MS/MS) on a Thermo Fisher LTQ Orbitrap Velos mass spectrometer fitted with a New Objective Digital PicoView 550 NanoESI source. Online HPLC separation of the digests was accomplished with an Eksigent/ AB Sciex NanoLC Ultra 2 D HPLC system: column, PicoFrit {New Objective; 75 fJID i.d.) packed to 15 em with CIS adsorbent (Vydac; 218MSBS 5 pm, 300 A); mobile phase A, 0.5% acetic acid (HAc)/0.005% trifluoroacetic acid (TFA); mobile phase B, 90% ACN/0.5% HAc/0.005% TFA; gradient 2-42% B in 120 min; flow rate, 0.4 pL/min. Precursor ions were acquired in the Orbitrap in centroid mode at 60,000 resolution (mlz 400); data dependent collision induced dissociation ( CID) spectra of the 10 most intense ions in the precursor scan above a threshold of 3,000 were acquired at the same time in the linear trap (isolation window for MS/MS, 3; relative collision energy, 30). Ions with a 1 + or unassigned charge state were not fragmented. Dynamic exclusion settings were: repeat count, 1; repeat duration, 30 s; exclusion list size, 500; exclusion duration, 30 s.
i@tiM
BioiD Proximity-Dependent Biotinylation Proteomics. Three 15 em plates of 293 cells were transfected with BioiD EWS Fli 1 (Myc tag and BirA Rll8G mutant fused to theN terminus of EWS Fli 1). Twenty four hours after transfection, biotinylation of proteins in the vicinity of BioiD EWS Fli 1 within the cells was induced for 24 h by the addition of 50 pM biotin to the culture medium. The cells were lysed by boiling in a lysis buffer (50 mM Tris, pH 7.4/500 mM NaCI/0.4% SDS/5 mM EDTA/1 mM DTT/1 mM AEBSF/10 pg/mL aprotinin/ 10 pg/mL Leupeptin/1 pg/mL Pepstatin A/20 mM sodium fluoride). The viscosity of the sample was reduced by passing it through an 18 gauge needle followed by sonication. Triton X 100 was added to 2% final concentration, and the biotinylated proteins were purified using streptavidin agarose (Pierce/ Thermo Fisher) and eluted in an SDS PAGE sample buffer.
The proteins in each sample were fractionated by SDS PAGE and visualized by Coomassie blue. Each gel lane was divided into six slices, and the proteins in each slice were digested in situ with trypsin (Promega modified) in 40 mM NH 4 HC0 3 overnight at 37 °C. The resulting tryptic peptides were analy-Led by HPLC ESI MS/MS as described above, except that a 30 min HPLC gradient was employed and the six most intense ions in the precursor scan were fragmented.
Mass Spectrometry Data Analysis
The Xcalibur raw files were converted to mzXML format using ReAdW (http: I It ools. proteom ecenter .org/wiki/ index. php?title=Software:ReAdW) and were searched against the IPI human protein database {v 3.24; 66,923 protein entries) using X! Tandem. Methionine oxidation was considered as a variable modification in all searches, and lysine biotinylation was included for the BioiD experiments. Up to one missed tryptic cleavage was allowed The X! Tandem search results were analyzed by the Trans Proteomic Pipeline 14 version 4.3.
Peptide/protein identifications were validated by Peptide/ ProteinProphet.
•
16 A ProteinProphet score of 0.9 was used as a cutoff, which corresponded to false identification rates of 1.1% and 0.7% in the FLAG His EWS Fli 1 and BioiD EWS Fli 1 data sets, respectively. lmmunoblotting Immunoblotting was performed as described. in the manufacture's gra dient dilution buffer, with an aliquot of the supernatant saved as the input fraction. The lysosome enrichment gradient was centrifuged at 145,000g using a SW60Ti rotor (Beckman Coulter) for 2 hat 4 °C. The top layer of the gradient, which contains the lysosomes, was collected, diluted with two volumes phosphate buffered saline, and centrifuged at 16,000g for 30 min at 4 °C. The resulting lysosome pellet was washed once in gradient dilution buffer and dissolved in SDS PAGE sample buffer. For immunoblotting analysis, the lysosome fraction was loaded at 100x compared to the input.
• RESULTS AND DISCUSSION
Proteomic Analysis of the EW$-Fii-1 -lnteracting Proteins
To dissect the EWS Fli 1 interactome, we initially employed a tandem affinity purification approach. We expressed FLAG His tagged EWS Fli 1 in human embryonic kidney 293T cells and isolated the EWS Fli 1 containing protein complex by nickel agarose chromatography followed by anti FLAG immunopre cipitation, which was subsequently analyzed by HPLC ESI MS/ MS as described in the Experimental Procedures ( Figure 1A) . At a Protein Prophet probability score of 0.9 or higher, 105 different proteins were identified (Table $1 ). To exclude the false positive identifications, we employed the data sets obtained using two unrelated nuclear proteins, p21 ( CDKN1A) and histone macroH2A The proteins commonly identified by FLAG His EWS Fli 1 and FLAG His p21 or FLAG His macroH2A with a Protein Prophet probability score of 0.9 or higher were considered as false positive 3785 identifications (the list of these proteins is shown in Table $ 2 ). After subtracting these false positive identifications, 54 proteins remained in the FLAG His EWS Fli 1 data set {shown in Table  S3 ), including known EWS Fli 1 interactors such as EWS ( Figure IB ; Note that two EWS C terminal peptides, which are absent in EWS Fli 1, were identified) 8 and RNA helicase A ( Figure 1C) . 9 While the tandem affinity purification approach identified known interactors for EWS Fli 1, we noticed that the majority of FLAG His EWS Fli 1 expressed in 293T cells was not solubilized under the non denaturing solubilization conditions used for tandem affinity purification ( Figure 1D) . Therefore, as an alternative approach to dissect the EWS Fli 1 interactome, we used the proximity dependent biotinylation technique, BioiD. 10 In the BioiD approach, a bait protein is fused to a mutated BirA biotinylase (BirA Rll8G) which promiscuously biotinylates the lysine residues of proteins in the vicinity (within 20-30 nm). The biotinylated vicinal proteins are purified by streptavidin affinity chromatography and are identified by mass spectrometry. The BioiD approach does not require the purification of a stable protein complex under non denaturing conditions and is useful for the analysis of insoluble protein complexes or transient low affinity interactions. It has been successfully applied to identify interactors for nuclear lamin A, 10 whose insolubility has hampered the analysis of its interactors, and to identify the protein components of bilobe, 17 an insoluble cytoskeletal structure in Trypanosoma brucei.
We expressed BioiD tagged EWS Fli 1 in human embryonic kidney 293 cells, induced the biotinylation of the proteins in the vicinity of BioiD EWS Fli 1 by 50 JtM biotin, and isolated the biotinylated proteins by streptavidin affinity chromatog raphy (Figure 2A) probability score of 0.9 or higher, 561 different proteins were identified (Table $4 ). To exclude the false positive identi fications, we employed the CRAPome database, 18 which is a "contaminant repository for affinity purification". Using CRAPome version 1.1 (http:/ /www.crapome.org/), 12 control proximity dependent biotinylation experiments performed in 293 cells were compiled. The proteins detected with five or more spectral counts per control experiment were considered as false positive identifications by the proximity dependent biotinylation approach. The list of these false positive identifications is shown in After excluding the false positive identifications, 54 proteins were identified from FlAG His EWS Fli 1 affinity purification and 366 proteins were identified from BioiD EWS Fli 1 analysis, and of these, four proteins were in common: EWS Fli 1, HNRNPA3, U2AF1, and EWS. Additionally, different isoforms of SUMO proteins were identified in both FLAG His EWS Fli 1 and BioiD EWS Fli 1 experiments. We note that there is a possible SUMO binding motif (LELLSDS, residues 340-346) in EWS Fli 1, which could mediate the interaction with SUMO proteins. EWS Fli 1 does not contain a sumoylation motif (hydrophobic K X E), and we have not been able to detect its sumoylation (data not shown).
3786
Among the high scoring proteins identified by the BioiD approach, cation independent mannose 6 phosphate receptor ( CIMPR) caught our attention because the detection of CIMPR, which is a cargo that mediates the sorting of lysosomal hydrolase precursors from the trans Golgi network to endo somes, 11 using BioiD EWS Fli 1 suggested a possible new link between EWS Fli 1 and the endosome-lysosome system. Molecular biological characterization of EWS Fli 1, performed in parallel with the proteomic analyses, demonstrated that EWS Fli 1 is a relatively stable protein and does not turn over by a proteasome dependent mechanism (described below), which led us to consider a possibility that EWS Fli 1 turns over by a lysosome dependent mechanism.
In the BioiD EWS Fli 1 experiment, 17 unique and 19 total peptides from CIMPR were identified ( Figure 2B and Table  S6 ). Consistent with the identification of CIMPR by the BioiD approach, we observed the coimmunoprecipitation of FLAG EWS Fli 1 and endogenous CIMPR upon treatment with chloroquine, an inhibitor oflysosomal degradation ( Figure 2C ). It is noteworthy that CIMPR was identified by the BioiD approach using only three 15 em plates of cells whereas it was not identified by the tandem affinity purification approach using 40 15 em plates of cells {even though the latter used 293T cells which generally result in higher protein expression levels than 293 cells employed in the former). We believe this is related to the insolubility of EWS Fli 1 under the solubilization conditions used for tandem affinity purification (Figure lD ) . 348 peptides derived from EWS Fli 1 were identified by the BioiD approach using three 15 em plates (Table S6) whereas 120 peptides derived from EWS Fli 1 were identified by the tandem affinity purification approach using 40 15 em plates (Table S3 ) , suggesting the efficient solubilization of EWS Fli 1 by the BioiD lysis buffer which contains 0.4% SDS. Our result as well as two previous BioiD studies 10 ' 17 suggest the utility of the BioiD approach for the dissection of protein-protein interactions involving insoluble proteins.
EW$-Fii-1 Turnover Occurs via a Lysosome-Dependent Mechanism
The protein transport function of CIMPR is regulated by the retromer complex, which redirects CIMPR from the endosome to the trans Golgi network.
19
,20 Interestingly, knockdown of CIMPR or VPS26A, an essential component of the retromer, resulted in reduced EWS Fli 1 protein expression ( Figure 3A) . 3787 This raised a possibility that EWS Fli 1 is transported to the late endosome and degraded by the lysosome, especially when CIMPR and retromer functions are compromised. Importantly, we found that coexpression of TFEB, a potent inducer of lysosomal biogenesis, 21 resulted in striking degradation of EWS Fli 1 ( Figure 3B ). Conversely, inhibition of lysosomal degradation by chloroquine stabilized EWS Fli 1 ( Figure 3C ).
Lysosomes contain many hydrolases that degrade various biomolecules, including proteins. We found that one of the lysosomal proteases, cathepsin D, can degrade EWS Fli 1, which was inhibited by chloroquine or a cathepsin D inhibitor, pepstatin A ( Figure 3D ). Cathepsin D did not degrade p53 ( Figure 3D JlM chloroquine fur 12 h or left tmtreated, and the luciferase activity was determined using the same arnotmt of protein lysate (left). The cells were treated with 300 nM torin 1 for 24 h or left untreated, and the luciferase activity was determined using the same arnotmt of protein lysate (right).
left). Endogenous EWS Fli 1 in A673 cells was not stabilized by a proteasome inhibitor, MG 132 ( Figure 3F, right) . Using subcellular fractionation, we detected endogenous EWS Fli 1 in the lysosomal fraction, which increased upon chloroquine treatment ( Figure 3G ). An abundant lysosomal glycoprotein,
3788
IAMP2, was readily detectable in the lysosomal fraction whereas a nuclear transcriptional corepressor mSin3A, which is not known to be located in the lysosome, was absent ( Figure  3G ). p62/SQSfM1, a known substrate of lysosomal degrada tion, displayed increased lysosomal location upon chloroquine Journal of Proteome Research treatment ( Figure 3G ). These results indicate that EWS Fli 1 is degraded by the lysosome.
Targeting EW$-Fii-1 for Degradation
We employed a translational inhibitor, cycloheximide, to inhibit the new protein synthesis in Ewing sarcoma cells and analyzed the turnover of endogenous EWS Fli 1 protein. While the EWS Fli 1 protein levels did not exhibit any significant decrease after 24 h treatment with cycloheximide, the sensitivity of Ewing sarcoma cells to cycloheximide did not allow us to continue the cycloheximide treatment to observe the turnover of EWS Fli 1, which is consistent with a previous report. 22 The toxicity of translation inhibitors such as ~cloheximide was attributed to the depletion of ubiquitin. Therefore, we exogenously expressed ubiquitin in Ewing sarcoma cells, which made the cells less sensitive to cycloheximide, and analyzed EWS Fli 1 turnover upon prolonged cycloheximide treatment. We observed some decay of EWS Fli 1 after 72 h treatment with cycloheximide ( Figure 4A ). In contrast, c Myc [half life = ....,30 min 24 ) and cyclin D1 [halflife <30 min 25 ) displayed the expected rapid decay upon cycloheximide treatment ( Figure 4A ). Our data suggest that endogenous EWS Fli 1 is a relatively stable protein, which agrees with the previous findings on transfected EWS Fli 1 26 and Fli 1.
27
Since EWS Fli 1 is a stable protein, there is a large therapeutic window to enhance its degradation. There are a few previously reported compounds that reduce EWS Fli 1 protein levels. Rapamycin, an mTOR allosteric inhibitor, was reported to diminish EWS Fli 1 protein levels in several Ewing sarcoma cell lines. 28 A screening for chemical compounds that inhibit the EWS Fli 1 mediated gene expression signature identified cytosine arabinoside, which was later shown to reduce the EWS Fli 1 protein levels in Ewing sarcoma cells. 29 The same study also demonstrated that doxorubicin, one of the standard chemotherapeutic agents for treating Ewing sarcoma, can reduce EWS Fli 1 protein levels in Ewing sarcoma cells. However, using the conditions described in refs 28 and 29, we have been unable to reproduce the reported effects of cytosine arabinoside, doxorubicin, and rapamycin on EWS Fli 1 protein levels ( Figure 4B-D) . A transcription factor TFEB recently emerged as a master regulator of lysosomal biogenesis. 21 The activity of TFEB is controlled by cytoplasmic sequestration, which is regulated by mTOR mediated phosphorylation. 30 -32 A potent mTOR active site inhibitor, torin 1, was shown to efficiently induce the nuclear translocation ofTFEB. 30 -32 In contrast, rapamycin, an mTOR allosteric inhibitor that only incompletely inhibits mTOR activity, did not induce TFEB nuclear translocation at any of the concentrations that are routinely used (10 nM -10 pM).
30
,3
1 We found that torin 1 treatment of Ewing sarcoma cells resulted in reduced EWS Fli 1 protein levels ( Figure 4E ), suggesting a potential therapeutic utility of mTOR active site inhibitors against Ewing sarcoma
We also devised the fusion of EWS Fli 1 and firefly luciferase to monitor the EWS Fli 1 protein levels. The luciferase activity derived from the luciferase-EWS Fli 1 fusion protein increased upon chloroquine treatment and decreased by torin 1 treatment ( Figure 4F ), further supporting that EWS Fli 1 turns over by a lysosome dependent mechanism, which can be enhanced by torin 1. In addition, this luciferase reporter can be used in the future to screen for compounds that target EWS Fli 1 for degradation.
i@tiM
Since the discovery of chromosomal translocation generating the EWS Fli 1 fusion oncogene and the pivotal role played by the transcriptional activity of EWS Fli 1 in Ewing sarcoma, several attempts have been made to target the transcriptional activity of EWS Fli 1. Stegmaier et a!. screened a small molecule library for compounds that inhibit the gene expression signature mediated by EWS Fli 1 in A673 Ewing sarcoma cells and identified cytosine arabinoside as an EWS Fli 1 modulator? 9 Erkizan et al. employed surface plasmon resonance screening for compounds that bind EWS Fli 1 and identified a small molecule that blocks the interaction of EWS Fli 1 and RNA helicase A, leading to suppression of EWS Fli 1 transcriptional activity and Ewing sarcoma growth. 33 Grohar et a!. employed a high throughput screen {luciferase reporter screen followed by a gene signature secondary screen) to evaluate over 50,000 compounds for inhibition of EWS Fli 1 transcriptional activity and identified mithramycin as an EWS Fli 1 inhibitor displaying anti Ewing sarcoma activity. 34 Boro et a!. used four EWS Fli 1 transcriptional target genes as readout to screen for compounds that abrogate EWS Fli 1 transcrip tiona! activity and identified a kinase inhibitor, midostaurin, which induced apoptosis in Ewing sarcoma cells. 35 While these seminal attempts provided important insights into Ewing sarcoma biology, an EWS Fli 1 targeted therapy has not reached clinical translation and EWS Fli 1 remains "the perfect target without a therapeutic agent"? Our findings that EWS Fli 1 turns over by a lysosome dependent mechanism and that an mTORC1 active site inhibitor can reduce the EWS Fli 1 protein levels in Ewing sarcoma cells suggest a potential therapy by targeting EWS Fli 1 for degradation.
• CONCLUSIONS Proteomic analysis of the EWS Fli 1 interactome led to the discovery of the role for the lysosome in EWS Fli 1 protein turnover. We demonstrated that EWS Fli 1 is a stable protein, which provides a large therapeutic window to enhance its degradation. We found that an mTORC1 active site inhibitor, torin 1, which stimulates the TFEB lysosome pathway, can induce the degradation of EWS Fli 1 in Ewing sarcoma cells. mTORC1 active site inhibitors could target both the depend ence of Ewing sarcoma on IGF mTOR signaling and EWS Fli 1 protein turnover and are potentially more effective than mTOR allosteric inhibitors as therapy for Ewing sarcoma.
• ASSOCIATED CONTENT e Supporting Information Table S1 : Preliminary list of FLAG His EWS Fli 1 interacting proteins. Table S2 : List of proteins commonly identified by FLAG His EWS Fli 1 and FLAG His p21 or FLAG His macro H2A Table S3 : List of FLAG His EWS Fli 1 interacting proteins after exclusion of proteins in Table S2 . Table S4 : Preliminary list of proteins identified by proximity dependent biotinylation using BioiD EWS Fli 1. Table SS: List of false positive identifications by proximity dependent biotinylation derived from the CRAPome database. Table $6 : List of proteins identified by proximity dependent biotinylation using BioiD EWS Fli 1 after exclusion of proteins in Table SS. Tables S1  and S4 list the proteins identified with a Protein Prophet probability score of 0.9 or higher, which corresponded to false identification rates of 1.1% and 0.7% in FlAG His EWS Fli 1 and BioiD EWS Fli 1 data sets, respectively. This material is available free of charge via the Internet at http:/ /pubs.acs.org. 
